Home › Compare › NEVPF vs BTI

NEVPF vs BTI: Dividend Comparison 2026

NEVPF yields 7142.86% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEVPF wins by $2020155342665731.25M in total portfolio value
10 years
NEVPF
NEVPF
● Live price
7142.86%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2020155342665731.25M
Annual income
$1,966,011,161,323,515,200,000.00
Full NEVPF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — NEVPF vs BTI

📍 NEVPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEVPFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEVPF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NEVPF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEVPF
Annual income on $10K today (after 15% tax)
$607,142.86/yr
After 10yr DRIP, annual income (after tax)
$1,671,109,487,124,987,800,000.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, NEVPF beats the other by $1,671,109,487,124,987,800,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEVPF + BTI for your $10,000?

NEVPF: 50%BTI: 50%
100% BTI50/50100% NEVPF
Portfolio after 10yr
$1010077671332865.63M
Annual income
$983,005,580,661,757,600,000.00/yr
Blended yield
97.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

NEVPF
No analyst data
Altman Z
-0.7
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEVPF buys
0
BTI buys
0
No recent congressional trades found for NEVPF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEVPFBTI
Forward yield7142.86% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$2020155342665731.25M ✓$37.7K
Annual income after 10y$1,966,011,161,323,515,200,000.00 ✓$2,786.64
Total dividends collected$2016528271361529.00M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NEVPF vs BTI ($10,000, DRIP)

YearNEVPF PortfolioNEVPF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$724,986$714,285.71$11,299$598.92+$713.7K → NEVPF
2$49,172,645$48,396,910.17$12,794$703.91+$49.16M → NEVPF
3$3,120,421,331$3,067,806,600.72$14,518$829.07+$3120.41M → NEVPF
4$185,281,229,916$181,942,379,091.82$16,513$978.64+$185281.21M → NEVPF
5$10,294,691,143,508$10,096,440,227,497.77$18,827$1,157.84+$10294691.12M → NEVPF
6$535,299,070,050,255$524,283,750,526,701.75$21,518$1,373.12+$535299070.03M → NEVPF
7$26,050,796,629,539,330$25,478,026,624,585,550.00$24,657$1,632.46+$26050796629.51M → NEVPF
8$1,186,669,129,317,434,600$1,158,794,776,923,827,700.00$28,329$1,945.74+$1186669129317.41M → NEVPF
9$50,602,038,637,584,920,000$49,332,302,669,215,270,000.00$32,637$2,325.33+$50602038637584.88M → NEVPF
10$2,020,155,342,665,731,300,000$1,966,011,161,323,515,200,000.00$37,708$2,786.64+$2020155342665731.25M → NEVPF

NEVPF vs BTI: Complete Analysis 2026

NEVPF — Stock

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Full NEVPF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this NEVPF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEVPF vs SCHDNEVPF vs JEPINEVPF vs ONEVPF vs KONEVPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.